Related Experiment Video
Updated: Jul 20, 2026

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
Published on: November 30, 2022
Managing biotechnology in a network-model health plan: a U.S. private payer perspective
John B Watkins1, Sanchita Roy Choudhury, Ed Wong
1Premera Blue Cross in Mountlake Terrace, Washington, USA. john.watkins@premera.com
Abstract:
Emerging biotechnology poses challenges to payers, including access, coverage, reimbursement, patient selection, and affordability. Premera Blue Cross, a private regional health plan, developed an integrated cross-functional approach to managing biologics, built around a robust formulary process that is fast, flexible, fair, and transparent to stakeholders. Results are monitored by cost and use reporting from merged pharmacy and medical claims. Utilization management and case management strategies will integrate with specialty pharmacy programs to improve outcomes and cost-effectiveness. Creative approaches to provider reimbursement can align providers' incentives with those of the plan. Redesign of member benefits can also encourage appropriate use of biotechnology.
Related Concept Videos
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Health Information Technology and Healthcare Information System
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic illness...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Drug Products: Biologics, Biosimilars and Interchangeables
